A double-blind, placebo-controlled study with open-label follow-up to determine the safety and efficacy of subcutaneous doses of r-HuEPO [recombinant human erythropoietin] in AIDS patients with anemia induced by their disease and AZT [zidovudine] therapy.

Trial Profile

A double-blind, placebo-controlled study with open-label follow-up to determine the safety and efficacy of subcutaneous doses of r-HuEPO [recombinant human erythropoietin] in AIDS patients with anemia induced by their disease and AZT [zidovudine] therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Ortho Biotech
  • Most Recent Events

    • 07 Jul 2009 Actual patient number (102) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Actual patient number (102) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top